Real‐world impact of a subsidy decision of sofosbuvir–velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes

Real‐world impact of a subsidy decision of sofosbuvir–velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes

Abstract Background and Aim Sofosbuvir–velpatasvir was recommended for subsidy to treat chronic hepatitis C in Singapore in 2018. We measured the impact of the subsidy decision on clinical practice and patient outcomes. Specifically, we looked at pre‐ and post‐subsidy changes in the utilization and...

Full description

Bibliographic Details
Main Authors: Chee‐Kiat Tan, Xue‐Shi Luo, Benjamin Shao‐Kiat Ong, Liang Lin, Kwong‐Hoe Ng
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:JGH Open
Subjects:
chronic hepatitis C
clinical practice
patient outcomes
real‐world impact
sofosbuvir–velpatasvir
Online Access:https://doi.org/10.1002/jgh3.12850

Similar Items

Similar Items